Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07490132 · ClinicalTrials.gov registry record
Endoscopic Retrograde Cholangiopancreatography
A clinical trial, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 100
- Enrollment target
NCT07490132: Recruiting study, sponsored by Methodist Health System.
NCT07490132 is a clinical trial that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07490132 is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
Primary Outcome
Patients undergoing ERCPs at Methodist Dallas Medical Center.
Interventions
- OTHER Patients undergoing ERCPs at Methodist Dallas Medical Center
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-02 |
What NCT07490132 shows while recruiting
NCT07490132 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Patients undergoing ERCPs at Methodist Dallas Medical Center is the first listed.
NCT07490132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07490132 about?
NCT07490132 is a clinical study titled "Endoscopic Retrograde Cholangiopancreatography". The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
What is the current status of trial NCT07490132?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2026-02. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07490132?
The interventions under investigation include: Patients undergoing ERCPs at Methodist Dallas Medical Center (OTHER).
Who is sponsoring clinical trial NCT07490132?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia